PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.29%
EBIT growth below 50% of AGEN's 34.21%. Michael Burry would suspect deeper competitive or cost structure issues.
3.29%
Operating income growth under 50% of AGEN's 34.21%. Michael Burry would be concerned about deeper cost or sales issues.
27.01%
Net income growth at 75-90% of AGEN's 30.84%. Bill Ackman would press for improvements to catch or surpass competitor performance.
26.90%
EPS growth at 50-75% of AGEN's 42.45%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
26.90%
Diluted EPS growth at 50-75% of AGEN's 42.45%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.31%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
3.31%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.36%
Negative 10Y OCF/share CAGR while AGEN stands at 54.08%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-12.36%
Negative 5Y OCF/share CAGR while AGEN is at 63.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-12.36%
Negative 3Y OCF/share CAGR while AGEN stands at 68.08%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
44.63%
Below 50% of AGEN's 89.36%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
44.63%
5Y net income/share CAGR at 50-75% of AGEN's 69.21%. Martin Whitman might see a shortfall in operational efficiency or brand power.
44.63%
3Y net income/share CAGR 50-75% of AGEN's 65.09%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
-80.42%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-80.42%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-80.42%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-16.23%
We have a declining book value while AGEN shows 0.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
14.30%
Debt growth far above AGEN's 1.38%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.62%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.